|
Cohort1: dose level 1
|
| Administration route |
infusion |
| Dosage |
1E7 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort2: dose level 2
|
| Administration route |
infusion |
| Dosage |
3E7 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort3: dose level 3
|
| Administration route |
infusion |
| Dosage |
1E8 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
No serious clinical adverse events |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort4: dose level 4
|
| Administration route |
infusion |
| Dosage |
3E8 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort5: dose level 5
|
| Administration route |
infusion |
| Dosage |
1E9 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort6: dose level 6
|
| Administration route |
infusion |
| Dosage |
3E9 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
none(grade 3 or higher) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort7: dose level 7
|
| Administration route |
infusion |
| Dosage |
1E10 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality); 1/1(Blood and lymphatic system disorders; Psychiatric disorders; Renal and urinary disorders) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort8: dose level 8
|
| Administration route |
infusion |
| Dosage |
3E10 cells |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort9: dose level 9
|
| Administration route |
infusion |
| Dosage |
1E11 cells |
| Donor type |
autologous |
| Pts |
6 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
4/6(PD) |
| Adverse reactions |
5/6(All-cause mortality); 3/6(Blood and lymphatic system disorders; Cardiac disorders; Infections and infestations; Psychiatric disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort10: dose level 10_Other Cancer
|
| Administration route |
infusion |
| Dosage |
Maximum Tolerated Dose |
| Donor type |
autologous |
| Pts |
5 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
4/5(PD) |
| Adverse reactions |
4/5(All-cause mortality); 3/5(Blood and lymphatic system disorders; Gastrointestinal disorders; Infections and infestations; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
| References |
PMID:
27163739 |
28809608
|
|
|
Cohort11: dose level 10_Melanoma
|
| Administration route |
infusion |
| Dosage |
Maximum Tolerated Dose |
| Donor type |
autologous |
| Pts |
1 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
1/1(PD) |
| Adverse reactions |
1/1(All couse mortality); 1/1(Blood and lymphatic system disorders) |
| References |
PMID:
27163739 |
28809608
|
|